Pfizer Inc. (NYSE:PFE) is one of the best dividend stocks to buy, according to hedge funds.
On June 24, the US Food and Drug Administration approved the use of Pfizer Inc. (NYSE:PFE)’s Ibrance in combination with trastuzumab as a maintenance option for patients with HR-positive, HER2-positive locally advanced or metastatic breast cancer after induction treatment
With the approval, Ibrance becomes the first and only CDK4/6 inhibitor indicated for patients with HR+ metastatic breast cancer. Piotr Kowalski/ The approval comes at the backdrop of topline results from the phase 3 Patina study that showed Ibrance reduced the risk of disease progression or death by 24% in the specific patient population. Additionally, the approval asserts Pfizer’s ongoing leadership in delivering meaningful advances for people with breast cancer.
Pfizer Inc. (NYSE:PFE) is a global biopharmaceutical company that discovers, develops, and manufactures prescription medicines, vaccines, and consumer healthcare products. It operates internationally to address critical health challenges across major therapeutic areas, including infectious diseases and immunology, oncology, and rare diseases. While we acknowledge the potential of PFE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk.